Abstract
Gliomas account for approximately 70% of primary brain tumors in adults. Of all gliomas, grade IV astrocytoma, also called glioblastoma, has the poorest overall survival, with <5% of patients surviving five years after diagnosis. Due to the aggressiveness, lethal nature, and impaired surgical accessibility of the tumor, early diagnosis of the tumor and, in addition, prediction of the patient’s survival time are important. We hypothesize that combining the protein level values of highly recognizable glioblastoma serum biomarkers could help to achieve higher specificity and sensitivity in predicting glioma patient outcome as compared to single markers. The aim of this study was to select the most promising astrocytoma patient overall survival prediction variables from five secretory proteins—glial fibrillary acidic protein (GFAP), matrix metalloproteinase-2 (MMP-2), chitinase 3-like 1 (CHI3L1), osteopontin (OPN), and amphiregulin (AREG)—combining them with routinely used tumor markers to create a Patient Survival Score calculation tool. The study group consisted of 70 astrocytoma patients and 31 healthy controls. We demonstrated that integrating serum CHI3L1 and OPN protein level values and tumor isocitrate dehydrogenase 1 IDH1 mutational status into one parameter could predict low-grade astrocytoma patients’ two-year survival with 93.8% accuracy.
Highlights
Gliomas account for approximately 70% of primary brain tumors in adults [1]
OPN protein level values and tumor isocitrate dehydrogenase 1 IDH1 mutational status into one parameter could predict low-grade astrocytoma patients’ two-year survival with 93.8% accuracy
All grade II astrocytoma cases were assigned to the low-malignancy astrocytoma group (LGG), and grade III cases, together with GBM, were assigned to the high-malignancy astrocytoma group (HGG)
Summary
Gliomas account for approximately 70% of primary brain tumors in adults [1]. The most common glioma type is astrocytoma, named for the shape-form cells—astrocytes—which they originate from.Even low-grade astrocytoma can progress to a more malignant one. Gliomas account for approximately 70% of primary brain tumors in adults [1]. The most common glioma type is astrocytoma, named for the shape-form cells—astrocytes—which they originate from. Even low-grade astrocytoma can progress to a more malignant one. Grade IV astrocytoma, called glioblastoma (GBM), has the poorest overall survival, with
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
